Gerardo San Pedro, MD
Critical Care Medicine · Bossier City, LANPI 1336166255
Payments from drug & device makers
Across 552 payments — averaging $137.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$34K
- GSK$34K
- Actelion Pharmaceuticals US, Inc.$2K
- AstraZeneca$2K
- Boehringer Ingelheim$843
- Insmed, Inc.$686
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$56,32074%
- Travel & lodging$7,36010%
- Food & beverage$11,77316%
- Education$4511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 42 | $33,798 |
| GSK | 156 | $33,516 |
| Actelion Pharmaceuticals US, Inc. | 78 | $1,858 |
| AstraZeneca | 68 | $1,759 |
| Boehringer Ingelheim | 39 | $843 |
| Insmed, Inc. | 24 | $686 |
| Paratek Pharmaceuticals, Inc. | 14 | $583 |
| Merck | 21 | $541 |
| United Therapeutics Corporation | 17 | $523 |
| Regeneron Healthcare Solutions, Inc. | 12 | $321 |
| Sanofi | 13 | $281 |
| Mylan Specialty L.p. | 7 | $167 |
| Inogen, Inc. | 9 | $109 |
| Bayer | 5 | $102 |
| ERBE USA Inc | 1 | $100 |
| Sunovion Pharmaceuticals Inc. | 8 | $69 |
| Shionogi Inc | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 4 | $59 |
| Johnson & Johnson | 4 | $56 |
| Amgen | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| Verona Pharma, Inc. | 2 | $44 |
| Mallinckrodt Hospital Products Inc. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Pfizer | 2 | $34 |
| La Jolla Pharmaceutical Company | 2 | $33 |
| Electromed, Inc. | 2 | $31 |
| Gilead | 2 | $30 |
| Itamar Medical Inc | 1 | $30 |
| Tactile Systems Technology Inc | 1 | $19 |
| Philips North America LLC | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$75,904 in reported general payments places this provider in the 90th percentile of 72 critical care medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 13 | $291,293 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 290 | $247,487 |
| OfevNintedanib Esylate | 17 | $226,533 |
| AdempasRiociguat | 15 | $207,757 |
| Ambrisentan | 22 | $65,150 |
| AdcircaTadalafil | 11 | $44,171 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $39,362 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 65 | $38,581 |
| Tadalafil | 22 | $32,885 |
| Atrovent HfaIpratropium Bromide | 37 | $26,298 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $24,436 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 37 | $23,156 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $21,915 |
| Spiriva RespimatTiotropium Bromide | 20 | $16,231 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $13,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $33,516 | $310,504391 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $843 | $305,282128 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $1,858 | $291,29313 claims |
| BayerAdempas | $102 | $207,75715 claims |
| United Therapeutics CorporationAdcirca | $523 | $44,17111 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,759 | $26,19150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 72 critical care medicine providers in Louisiana.
Other critical care medicine in Bossier City
- Raghu NathanBossier City$6K
- Abdulla Majid-MoosaBaton Rouge$202K
- Shaun YockelsonNew Orleans$179K
- Steven ConradShreveport$119K
- Jonathan EatonShreveport$106K
- James VermaelenBaton Rouge$27K
- Richard MorrisonShreveport$24K
- Laurie GrierShreveport$23K
- Fidencio DavalosLake Charles$20K
- William CantwellAlexandria$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.